Fig. 1

The clinical course of the disease. After the first hospitalization, the second to fourth coronary artery angiographies (CAGs) showed in-stent restenosis in the left main coronary artery (LMCA) and new stenosis of the left anterior descending (LAD) and left circumflex artery. Percutaneous transluminal coronary angioplasties were performed in the second to third hospitalization, and another drug-eluting stent (4.0 × 12 mm, PROMUS Element, Boston Scientific) was implanted in conjunction of LAD and LMCA in the fourth admission (November 2020). She consistently received anti-inflammation therapy and glucocorticoids tapered at 10 mg daily orally. Mycophenolate mofetil was changed to cyclophosphamide and successively cyclosporine A due to the twice bounce of erythrocyte sedimentation rate and C-reactive protein when in the outpatient of the rheumatology department. She took excimer laser coronary atherectomy and drug-coated balloon dilation in the fifth hospitalization. (A. CAGs of five times for the Takayasu’s arteritis patient; B. Erythrocyte sedimentation rate and C-reactive protein surveillance, and drug therapies)